180 related articles for article (PubMed ID: 12914745)
21. Effects of a growth hormone receptor antagonist on bone markers in acromegaly.
Fairfield WP; Sesmilo G; Katznelson L; Pulaski K; Freda PU; Stavrou S; Kleinberg D; Klibanski A
Clin Endocrinol (Oxf); 2002 Sep; 57(3):385-90. PubMed ID: 12201832
[TBL] [Abstract][Full Text] [Related]
22. Findings and theoretical considerations on the usefulness of the acid-labile subunit in the monitoring of acromegaly.
Morrison KM; Wu Z; Bidlingmaier M; Strasburger CJ
Growth Horm IGF Res; 2001 Jun; 11 Suppl A():S61-3. PubMed ID: 11527090
[TBL] [Abstract][Full Text] [Related]
23. Growth hormone receptor antagonists.
van der Lely AJ; Kopchick JJ
Neuroendocrinology; 2006; 83(3-4):264-8. PubMed ID: 17047392
[TBL] [Abstract][Full Text] [Related]
24. Place of pegvisomant in acromegaly.
Ho KK
Lancet; 2001 Nov; 358(9295):1743-4. PubMed ID: 11734225
[No Abstract] [Full Text] [Related]
25. Pegvisomant: an advance in clinical efficacy in acromegaly.
Stewart PM
Eur J Endocrinol; 2003 Apr; 148 Suppl 2():S27-32. PubMed ID: 12670298
[TBL] [Abstract][Full Text] [Related]
26. Successful treatment of resistant acromegaly with a growth hormone receptor antagonist.
Drake WM; Parkinson C; Akker SA; Monson JP; Besser GM; Trainer PJ
Eur J Endocrinol; 2001 Oct; 145(4):451-6. PubMed ID: 11581004
[TBL] [Abstract][Full Text] [Related]
27. Endogenous estradiol may influence IGF-I levels in acromegalic women treated with pegvisomant.
Roemmler J; Bidlingmaier M; Schopohl J
Pituitary; 2010; 13(1):89-93. PubMed ID: 18498055
[TBL] [Abstract][Full Text] [Related]
28. The role of pegvisomant in the treatment of acromegaly.
Roelfsema F; Biermasz NR; Pereira AM; Romijn JA
Expert Opin Biol Ther; 2008 May; 8(5):691-704. PubMed ID: 18407771
[TBL] [Abstract][Full Text] [Related]
29. Growth hormone receptor antagonist therapy in acromegalic patients resistant to somatostatin analogs.
Herman-Bonert VS; Zib K; Scarlett JA; Melmed S
J Clin Endocrinol Metab; 2000 Aug; 85(8):2958-61. PubMed ID: 10946911
[TBL] [Abstract][Full Text] [Related]
30. Treatment of acromegaly with the GH receptor antagonist pegvisomant in clinical practice: safety and efficacy evaluation from the German Pegvisomant Observational Study.
Schreiber I; Buchfelder M; Droste M; Forssmann K; Mann K; Saller B; Strasburger CJ;
Eur J Endocrinol; 2007 Jan; 156(1):75-82. PubMed ID: 17218728
[TBL] [Abstract][Full Text] [Related]
31. Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant.
Trainer PJ; Drake WM; Katznelson L; Freda PU; Herman-Bonert V; van der Lely AJ; Dimaraki EV; Stewart PM; Friend KE; Vance ML; Besser GM; Scarlett JA; Thorner MO; Parkinson C; Klibanski A; Powell JS; Barkan AL; Sheppard MC; Malsonado M; Rose DR; Clemmons DR; Johannsson G; Bengtsson BA; Stavrou S; Kleinberg DL; Cook DM; Phillips LS; Bidlingmaier M; Strasburger CJ; Hackett S; Zib K; Bennett WF; Davis RJ
N Engl J Med; 2000 Apr; 342(16):1171-7. PubMed ID: 10770982
[TBL] [Abstract][Full Text] [Related]
32. Efficacy of 12-month treatment with the GH receptor antagonist pegvisomant in patients with acromegaly resistant to long-term, high-dose somatostatin analog treatment: effect on IGF-I levels, tumor mass, hypertension and glucose tolerance.
Colao A; Pivonello R; Auriemma RS; De Martino MC; Bidlingmaier M; Briganti F; Tortora F; Burman P; Kourides IA; Strasburger CJ; Lombardi G
Eur J Endocrinol; 2006 Mar; 154(3):467-77. PubMed ID: 16498061
[TBL] [Abstract][Full Text] [Related]
33. The Effect of the Exon-3-Deleted Growth Hormone Receptor on Pegvisomant-Treated Acromegaly: A Systematic Review and Meta-Analysis.
Franck SE; Broer L; van der Lely AJ; Kamenicky P; Bernabéu I; Malchiodi E; Delhanty PJD; Rivadeneira F; Neggers SJCMM
Neuroendocrinology; 2017; 105(2):131-140. PubMed ID: 27513761
[TBL] [Abstract][Full Text] [Related]
34. [Growth hormone receptor antagonist in the treatment of acromegaly].
Hubina E; Tóth A; Kovács GL; Dénes J; Kovács L; Góth M
Orv Hetil; 2011 May; 152(18):709-14. PubMed ID: 21498159
[TBL] [Abstract][Full Text] [Related]
35. Plasma Agouti-Related Protein Levels in Acromegaly and Effects of Surgical or Pegvisomant Therapy.
Freda PU; Reyes-Vidal C; Jin Z; Pugh M; Panigrahi SK; Bruce JN; Wardlaw SL
J Clin Endocrinol Metab; 2019 Nov; 104(11):5453-5461. PubMed ID: 31361303
[TBL] [Abstract][Full Text] [Related]
36. Pegvisomant and improvement of quality of life in acromegalic patients.
Neggers SJ; van der Lely AJ
Horm Res Paediatr; 2011; 76 Suppl 1():102-5. PubMed ID: 21778759
[TBL] [Abstract][Full Text] [Related]
37. Pegvisomant Pfizer/Sensus.
Goffin V; Touraine P
Curr Opin Investig Drugs; 2004 Apr; 5(4):463-8. PubMed ID: 15134290
[TBL] [Abstract][Full Text] [Related]
38. Pharmacological approach to the treatment of acromegaly.
Ezzat S
Neurosurg Focus; 2004 Apr; 16(4):E3. PubMed ID: 15191332
[TBL] [Abstract][Full Text] [Related]
39. Does pegvisomant treatment expertise improve control of resistant acromegaly? The Italian ACROSTUDY experience.
Cannavo S; Bogazzi F; Colao A; De Marinis L; Maffei P; Gomez R; Graziano E; Monterubbianesi M; Grottoli S;
J Endocrinol Invest; 2015 Oct; 38(10):1099-109. PubMed ID: 25916431
[TBL] [Abstract][Full Text] [Related]
40. Medical treatment in acromegaly.
Paisley AN; Trainer PJ
Curr Opin Pharmacol; 2003 Dec; 3(6):672-7. PubMed ID: 14644022
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
